|
|
||||||||||||||
|
|
|||||||||||||||
Therapeutics |
Clinical impact ratings IM/Ambulatory care






Psychiatry 





Geriatrics 





GP/FP/Primary care 





Key Words: depressive disorder (major) paroxetine psychotherapy serotonin uptake inhibitors
| The first 150 words of the full text of this article appear below. |
METHODS
Design
randomised, 2 x 2 factorial design, placebo controlled trial.
Allocation
{concealed*}
.
Blinding
blinded (clinicians, patients, and outcome assessors).* Clinicians and patients were not blinded to the psychotherapy intervention.
Follow up period
2 years.
Setting
specialised university-based clinic in Pittsburgh, Pennsylvania, USA.
Patients
116 patients
70 years of age (mean age 77 y, 65% women) who had major depression according to the DSM-IV criteria, score
15 on the Hamilton Rating Scale for Depression (HRSD) (range 052 [worst]), score
17 on the Folstein Mini-Mental State Examination (range 030 [best]), and a sustained clinical response after several months of treatment with paroxetine, 1040 mg/day, and psychotherapy (weekly, then biweekly).
Intervention
paroxetine plus psychotherapy (n = 28), paroxetine plus clinical care (n = 35), placebo plus psychotherapy (n = 35), or placebo plus clinical care (n = 18) for 2 years. Paroxetine was continued at the individually titrated dose. Psychotherapy or clinical
John W Williams, Jr, MD, MHS
Duke University Medical Center, Durham, North Carolina, USA
Relevant Article
Evid. Based Med. 2006 11: 127.
(in Glossary)
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |